Clinical trial · Interventional
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
NCT03100955CI-TRIAL-00026779unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Progression Free Survival | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin, etoposide | Drug | — | UNRESOLVED |
| cisplatin, etoposide, apatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- EP chemotherapy
- description
- Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
- interventionNames
- Drug: cisplatin, etoposide
- type
- EXPERIMENTAL
- label
- EP chemotherapy plus apatinib
- description
- Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically verified SCLC, extensive stages 2. WHO performance status 0, 1, 2 3. Age 18 years or older 4. Treatment naive 5. Anticipated survival more than 3 months 6. HB \>90g/L, ANC\>1.5 x 109/L, Platelets \>80 x109 /L 7. No prognancy 8. Signed informed consent Exclusion Criteria: 1. Limited stage disease 2. Metastastic meningitis, spinal compression, Tumor to main vesicular less than 5mm 3. Uncontrolled hypertension 4. Uncontrolled heart failure 5. Coagulation problem 6. Surgery, trauma, uncontrolled ulcer in 4 weeks. 7. Required by physician
References
Publications (0)
Data not yet available
No reference posted for this study.